FDA approves oral Wegovy pill: first oral GLP-1 for weight loss

TL;DR

The FDA approved Wegovy as a once-daily pill in December 2025 - the first oral GLP-1 medication cleared for weight loss in the United States. The OASIS 4 trial showed roughly 17% average weight loss with full adherence over 64 weeks, at a launch price of $149 per month.

For millions of people who avoid injections - or simply want a more convenient option - this approval changes the practical calculus of GLP-1 treatment. Novo Nordisk's Wegovy has been available as a weekly injection since 2021. The pill version, semaglutide 25 mg tablets, was approved by the FDA on December 22, 2025, and launched in early January 2026 at a monthly price of $149 with savings offers. Shortly after, Eli Lilly's Foundayo (orforglipron) also received FDA approval - making 2026 the first year two oral GLP-1 medications for weight loss were on the market simultaneously.

What OASIS 4 showed

The approval rested on a 64-week Phase 3 trial called OASIS 4, involving 307 adults with obesity or overweight without type 2 diabetes. The results split into two sets of numbers depending on how you count adherence - both worth understanding:

• With full treatment adherence: approximately 17% average weight loss vs approximately 3% for placebo
• Regardless of adherence (including dropouts): approximately 14% average weight loss vs approximately 2% for placebo
• Percentage of patients achieving ≥5% weight loss: 76% on Wegovy pill vs 31% on placebo

Baseline weight in the Wegovy group averaged 235 lbs (107 kg); the placebo group averaged 231 lbs. The 17% figure under full adherence translates to approximately 40 lbs lost for someone starting at 235 lbs. The 14% figure under intent-to-treat analysis - the more conservative and clinically relevant number - is approximately 33 lbs.

Those numbers are meaningful. They are somewhat below the injectable Wegovy's 15.3% average under intent-to-treat conditions in the STEP-1 trial, which is expected: oral bioavailability of semaglutide is lower than injectable, even at the 25 mg tablet dose. But for someone who would not otherwise be on GLP-1 treatment because of injection aversion, 14% is substantially better than the 0% they were getting from nothing.

How the pill compares to Foundayo (orforglipron)

Foundayo - Eli Lilly's oral GLP-1 approved April 2026 - produced 12.4% average weight loss in its Phase 3 trials, compared to the approximately 14% for the Wegovy pill. Both are once-daily. Both are priced around the same range: Foundayo at approximately $149-$199/month, Wegovy pill at $149/month at launch.

The two pills work differently at the molecular level. Wegovy tablet is oral semaglutide - the same molecule as injectable Wegovy and Ozempic, formulated with an absorption enhancer (SNAC - sodium caprylamide) that helps the drug cross the stomach lining before acid degrades it. Foundayo (orforglipron) is a small-molecule GLP-1 receptor agonist - a chemically distinct compound that does not require an absorption enhancer and is easier to manufacture at scale.

One practical difference: the Wegovy pill must be taken first thing in the morning, on an empty stomach, with no more than 4 oz of plain water, and you must wait 30 minutes before eating or taking other medications. That is a meaningful constraint for people whose morning routines do not accommodate fasting windows. Foundayo has a simpler dosing protocol.

The cardiovascular indication

Like injectable Wegovy, the oral pill also carries an FDA approval to reduce major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with overweight or obesity and established heart disease. This is the same indication that came from the SELECT trial data for the injectable - and it applies to the pill formulation as well.

That dual indication matters. For patients who have both obesity and existing cardiovascular disease, the oral Wegovy pill is not just a weight loss drug - it is a cardiovascular risk reduction tool. That distinction affects insurance coverage in some plans and matters clinically for prescribers deciding between options.

Who the pill makes most sense for

Not everyone should immediately switch from injectable to oral. The pill produces somewhat less weight loss than the injection, and that gap matters if you are trying to achieve a specific threshold - say, 20% loss to qualify for a procedure or resolve a particular comorbidity. For that goal, injectable Wegovy or tirzepatide (Zepbound) remain more effective options.

The oral pill makes the most sense for:

• People who have injection anxiety or needle phobia that has been a barrier to starting GLP-1 treatment at all
• People managing a lighter weight loss goal (5-15%) who want convenience over maximum efficacy
• People who have already achieved significant weight loss on an injectable and want to transition to a lower-burden maintenance option
• People for whom the $149 monthly price is meaningfully lower than their out-of-pocket cost for the injectable

Safety profile: familiar territory

The adverse event profile of oral semaglutide mirrors the injectable: nausea, diarrhea, and vomiting are the most common. Serious warnings include the possibility of thyroid tumours (the same black-box warning carried by all semaglutide products), and the pill is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 syndrome.

Notably, a February 2026 JCI review found that orforglipron (Foundayo) showed a higher relative risk for nausea (RR 4.77) compared to semaglutide (RR 2.95) - so if GI tolerance is your primary concern, the oral semaglutide formulation may have an edge over Foundayo, at least based on current data.

Manufacturing and supply: Novo Nordisk's bet

Novo Nordisk announced manufacturing occurring in North Carolina with adequate supply ready at launch - a deliberate contrast to the injectable shortage that plagued Wegovy and Ozempic in 2022-2023. The company clearly does not want a repeat of that situation with the pill launch.

As of early 2026, supply appears stable. Whether it holds as prescription volume grows - especially under the Medicare GLP-1 Bridge program launching July 1, 2026, which makes Wegovy eligible at a $50/month cap for qualifying Medicare patients - remains to be seen.

What the pill does not change about GLP-1 nutrition needs

The route of administration is different. The nutritional consequences are the same. Whether semaglutide enters your body via injection or tablet, the appetite suppression and reduced food intake it creates carry the same risk of depleting vitamin D, vitamin B12, iron, and other micronutrients over time. A February 2026 meta-analysis of 480,825 adults found 13.6% rates of vitamin D deficiency and 64% rates of insufficient iron among GLP-1 users - regardless of formulation.

The pill does not make you immune to these gaps. If anything, some patients find that oral semaglutide's nausea (particularly during dose escalation) is more acute than the injectable's, which can temporarily reduce food intake further. Monitoring your nutrient levels and supplementing proactively is just as important on the pill as on the injection. GLP-1 Shield was designed around exactly this need - for users of every formulation of GLP-1 medications.

Frequently asked questions

How much weight can you lose on the Wegovy pill?

The OASIS 4 trial showed approximately 17% average weight loss with full adherence over 64 weeks, or approximately 14% under the intent-to-treat analysis that includes dropouts. For context, injectable Wegovy produces about 15.3% under intent-to-treat conditions in the STEP-1 trial. The pill is slightly less effective than the injection but still clinically meaningful.

How do you take the oral Wegovy pill?

Once daily, first thing in the morning, on an empty stomach, with no more than 4 oz (half a cup) of plain water. You must wait at least 30 minutes before eating, drinking anything other than plain water, or taking other oral medications. This fasting window is required for adequate absorption and cannot be skipped.

Is the Wegovy pill covered by insurance?

Coverage varies by plan. The Medicare GLP-1 Bridge program launching July 1, 2026 includes Wegovy (both injectable and pill) for eligible Medicare beneficiaries at a $50/month cap. For commercial insurance, coverage depends on whether your plan covers obesity treatment - many still do not. Novo Nordisk offers savings programs that bring the cost to $149/month for eligible commercially insured patients.

What is the difference between oral Wegovy and Foundayo (orforglipron)?

Both are once-daily oral GLP-1 medications approved for weight loss. Wegovy pill is semaglutide (the same molecule as injectable Wegovy) at 25 mg. Foundayo is orforglipron, a chemically different small-molecule GLP-1 receptor agonist. Wegovy pill produced about 14% weight loss in trials; Foundayo produced about 12.4%. Wegovy pill requires an empty-stomach morning dose; Foundayo has a simpler dosing protocol. Both are priced around $149-$199/month.